H.C. Wainwright Starts SteadyMed (STDY) at Buy; Sees High Likelihood of IPR Ruling in Favor of Company

November 7, 2016 7:21 AM EST
Get Alerts STDY Hot Sheet
Price: $2.90 --0%

Rating Summary:
    4 Buy, 0 Hold, 0 Sell

Rating Trend: Up Up

Today's Overall Ratings:
    Up: 20 | Down: 35 | New: 11
Trade STDY Now!
Join SI Premium – FREE

News and research before you hear about it on CNBC and others. Claim your 2-week free trial to StreetInsider Premium here.

H.C. Wainwright initiates coverage on SteadyMed (NASDAQ: STDY) with a Buy rating and a price target of $10.00.

Analyst Andrew Fein commented, "We believe that SteadyMed and its disposable treprostinil pump offer an atypical biotech investment opportunity which leverages the recent challenges and apparent decline of the Remodulin brand (weakening sales, IP vulnerability and legal settlements). Instead of the usual clinical, regulatory and commercial hoops that a typical biotech company must typically jump through, we believe that the main wager in play is a legal one: SteadyMed’s legal challenge of a United Therapeutics’ (UTHR; Neutral rated) key treprostinil patent. Based on our deep dive into the ongoing Inter Partes Review (IPR), a relatively new and unconventional method of IP challenge, we believe that there is a high likelihood for a ruling in favor of SteadyMed by next spring, or alternatively, a possibility for a value-driving settlement and/or business development in the interim. In anticipation of such legal win on the IPR front, with company's planned approval filing via the 505(b)(2) pathway in 1Q16, and de-risked regulatory and commercial prospects, we are initiating coverage with a Buy rating and $10 price target."

For an analyst ratings summary and ratings history on SteadyMed click here. For more ratings news on SteadyMed click here.

Shares of SteadyMed closed at $3.90 yesterday.



Serious News for Serious Traders! Try StreetInsider.com Premium Free!

You May Also Be Interested In






Related Categories

Analyst Comments, FDA, Hot New Coverage, New Coverage

Related Entities

H.C. Wainwright

Add Your Comment